11. |
Levetiracetam is an effective add-on therapy for refractory partial-onset epilepsy when assessed by seizure-free days, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
12. |
Zidovudine, lamivudine, efavirenz best triple regimen for HIV-1 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 13-13
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
13. |
Borage oil: no benefit in atopic dermatitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 14-14
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
14. |
Etanercept plus methotrexate slows the TEMPO of RA progression |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 15-16
C Bankhead,,
Preview
|
|
摘要:
Overexpression of tumour necrosis factor (TNF) in joints is a major contributor to the evolution and progression of rheumatoid arthritis (RA). Anti-TNF therapies have demonstrated efficacy in reducing joint pain and inflammation and slowing the progression of RA. A potential strategy to enhance therapeutic efficacy in RA is to combine an anti-TNF agent with a conventional disease-modifying antirheumatic drug (DMARD). This strategy has been evaluated in an international study involving over 600 patients with RA. Results from the study, which were presented at the 67th Annual Scientific Meeting of the American College of Rheumatology (ACR) [Orlando, US; October 2003], showed that combination therapy with the TNF receptor antagonist etanercept [Enbrel] plus the DMARD methotrexate resulted in significantly less radiographic progression of RA, and higher clinical response rates, compared with etanercept or methotrexate alone. Another study presented at the meeting indicated that early initiation of etanercept produced durable improvements in patients with RA. This study showed that initiating etanercept therapy in early-stage RA resulted in sustained inhibition of radiographic progression, and allowed a substantial number of patients to reduce the dosage of, or discontinue, corticosteroids and existing methotrexate therapy.
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
15. |
Pramipexole may be beneficial in patients with REM*sleep behaviour disorder, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 16-16
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
16. |
Switching to abacavir/lamivudine/tenofovir ineffective in HIV-1 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 17-17
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
17. |
Adequate minimum plasma concentrations of indinavir and ritonavir are achieved when given in combination with efavirenz, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 18-18
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
18. |
Benzodiazepines: increased risk of fracture-related mortality in elderly |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 19-19
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
19. |
Thiazolidinediones increase risk of heart failure |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 20-20
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|
20. |
US regulatory news |
|
Inpharma Weekly,
Volume &NA;,
Issue 1418,
2003,
Page 21-21
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2003
数据来源: ADIS
|